RxDoctor Payments Data

Maile Kane, DO

Family Medicine · Mesquite, NVNPI 1174552517

Payments from drug & device makers

$1,299in general payments, 2019–2025

Across 39 payments — averaging $33.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$495
  • Novo Nordisk$294
  • Amarin Pharma, Inc.$160
  • Pfizer$133
  • Lilly USA, LLC$31
  • Scilex Pharmaceuticals Inc.$23
  • plus $163 from 10 others

What the payments were for

  • Food & beverage$1,28199%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,299 in reported general payments places this provider in the 70th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$10,981
Medicare patients
82
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$52,516
OzempicSemaglutide27$32,353
XareltoRivaroxaban18$21,092
MyrbetriqMirabegron21$18,145
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$14,740
Rosuvastatin Calcium372$5,974
Amlodipine Besylate398$4,945
SymbicortBudesonide/Formoterol Fumarate12$4,712
Atorvastatin Calcium316$3,969
FenofibrateFenofibrate Nanocrystallized143$3,654
Levothyroxine Sodium266$3,327
Gabapentin80$3,296
Losartan Potassium192$3,006
Lisinopril263$2,656
Albuterol Sulfate HfaAlbuterol Sulfate63$2,373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$133$52,51637 claims
Novo NordiskOzempic$294$32,35327 claims
AstraZenecaSymbicort$495$4,71212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 902 family medicine providers in Nevada.

Other family medicine in Mesquite

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →